Concepedia

Author

Gaurav Bajaj

Bristol-Myers Squibb (United States)ORCID

Also Known As

G Bajaj, G. K. Bajaj, Gaurav Bajaj, Gopal Bajaj, Gupta, Metelkin Evgeny

95

Publications

1.6K

Citations

20

H-Index

48

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Princess Margaret Cancer CentreBristol-Myers Squibb (Sweden)Purdue University West LafayetteBristol-Myers Squibb (Germany)
GB

About

Gaurav Bajaj is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

453

2

Engineering

3

3

283

3

Health Sciences

2

2

59

4

Natural Sciences

1

1

106

5

Biochemistry

1

1

106

Gaurav Bajaj

×

19

Publications

1.3K

Citations

18

H-Index

YearCitations

Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors

Gaurav Bajaj, Xueyan Wang, Sachin Agrawal,

CPT Pharmacometrics & Systems Pharmacology

2016

249

Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors

Gaurav Bajaj, Mi Ran Kim, Sulma I. Mohammed,

Journal of Controlled Release

2011

141

Zwitterionic Chitosan Derivatives for pH-Sensitive Stealth Coating

Peisheng Xu, Gaurav Bajaj, Tyler Shugg,

Biomacromolecules

2010

106

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik, Elena Garralda, Friederike Gieseke,

Cancer Discovery

2022

104

Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer

Feng Yan, Xiaoning Wang, Gaurav Bajaj,

Clinical Cancer Research

2017

97

Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma

Xueyan Wang, Yu-yu Feng, Gaurav Bajaj,

CPT Pharmacometrics & Systems Pharmacology

2016

91

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors

Kimberley M. Heinhuis, Matteo S. Carlino, Markus Joerger,

JAMA Oncology

2019

90

Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors

Shruti Agrawal, Paul Statkevich, Gaurav Bajaj,

The Journal of Clinical Pharmacology

2016

72

Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology

Gaurav Bajaj, Satyendra Suryawanshi, Amit Roy,

British Journal of Clinical Pharmacology

2019

56

Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors.

Lillian L. Siu, Neeltje Steeghs, Tarek Meniawy,

Journal of Clinical Oncology

2017

53

Page 1